

DR PETER FRENCH DISCUSSES A\$31.5 MILLION PLACEMENT

Sydney Australia, 26 February 2014 : Benitec Biopharma Limited (ASX:BLT) is pleased to invite investors to listen to an audio interview of Managing Director and CEO, Dr Peter French providing further background to Monday 24th February's announcement that the company has entered into agreements for a Private Placement to raise approximately AUD \$31.5 million from institutional investors.

In this audiocast, Dr French discusses the following:

- The rationale behind undertaking the capital raising at this time, following strong US appetite in 2013/2014 for biotechnology investments and recent on-market support for Benitec;
- The transformation that Benitec's share register will undertake, with the inclusion of blue chip international institutional investors that will complement the Company's strong retail register;
- How the funding will allow Benitec to see its hepatitis C program through to completed phase IIb stage, and advance other programs in the company's pipeline including its lung cancer, age related macular degeneration, and hepatitis B programs

To listen to the audio, please copy the following link into your browser:

<http://www.brrmedia.com/event/120928>

Company	Investor relations
Carl Stubbings Chief Business Officer Tel: +61 (2) 9555 6986 Email: cstubbings@benitec.com	Jane Lowe Buchan Consulting Tel: +61 (2) 9237 2807 Email: jlowe@buchanwe.com.au

About Benitec Biopharma Limited: Benitec Biopharma Limited is an ASX-listed biotechnology company (ASX Code: BLT) based in Sydney, Australia. The company has a pipeline of in-house and partnered therapeutic programs based on its patented gene-silencing technology, ddRNAi. Benitec is developing treatments for chronic and life-threatening human conditions such as Hepatitis C, Hepatitis B, wet age-related macular degeneration, cancer-associated pain, drug resistant lung cancer and oculopharyngeal muscular dystrophy based on this technology. In addition, Benitec has licensed ddRNAi technology to other biopharmaceutical companies who are progressing their programs towards the clinic for applications including HIV/AIDS, retinitis pigmentosa and Huntington's disease. For more information on Benitec refer to the Company's website at www.benitec.com.